Rheumatoid Arthritis

CT-P10 is indicated to treat a form of non-Hodgkin lymphoma and rheumatoid arthritis.

New analysis examines opioid use among patients with rheumatoid arthritis.

Rheumatoid arthritis carries risks for several comorbidities that can affect organ systems, such as the heart and lungs.

Novel vaccine modulates T cell responses in RA.

Exposure to secondhand smoke in children can lead to RA later in life.

Top articles of the week on Specialty Pharmacy Times.

Additional support programs found to benefit the physical and emotional needs of patients with RA.

Eli Lilly will present 27 abstracts on the safety and long-term efficacy for rheumatoid arthritis and psoriasis drugs.

The drug offers a new therapeutic option to help manage RA.

Another state passes legislation to increase uptake of biosimilars.

Filgotinib may offer new option for patients with rheumatoid arthritis who have an inadequate response to methotrexate.

Top articles of the week from Specialty Pharmacy Times.

Both 15-mg and 30-mg doses of upadacitinib achieved desired endpoints in the treatment of rheumatoid arthritis.

Sandoz is seeking approval of biosimilars adalimumab and infliximab for use in all indications of their respective reference products.

Initiating biologics before triple therapy increases costs and provides minimal incremental benefit.

Switching from DMARDs to first-line biologics may not be the optimal treatment for RA.

RA patients can consume up to 14 alcoholic beverages per week without increasing the risk of liver damage, but rates increase with increasing levels of alcohol consumption.

Metastatic urothelial carcinoma drug among key approvals from May 2017.

Kevin Mange, MD, MSCE, head of North America Medical Immunology at Sanofi, provides a comprehensive overview of the considerations in the treatment of rheumatoid arthritis, which carries comorbidities that affect multiple organ systems.

Top articles of the week from The American Journal of Pharmacy Benefits.

Age-associated B cells found to contribute to autoimmune disorder prevalence in women.

Sarilumab plus DMARDs demonstrated statistically significant improvements in patients with moderate to severe RA.

Sarilumab is a human monoclonal antibody designed to bind to the interleukin-6 receptor.

The FDA has approved sarilumab (Kevzara) from Sanofi and Regeneron Pharmaceuticals for the treatment of adult patients with moderately to severely active rheumatoid arthritis.

Altered stem cells are capable of developing into cartilage cells that create a biologic anti-inflammatory drug.